Luspatercept: all 46 studies that test it

Page 1 of 1. Open to participants first (20), then studies with results posted, then the rest; newest registration first within each.

• Plasmatic Biomarkers Associated With Short-term Luspatercept Treatment of Lower Risk Myelodysplastic Syndromes (MDS) PatientsNot yet recruitingNCT07830004Phase 4
• A Study of Luspatercept in People With AnemiaRecruitingNCT07725497Phase 2
• Luspatercept for CIA in AMLRecruitingNCT07663864Phase 1/2
• Luspatercept vs Epoetin in Treating Poor Erythroid Engraftment for Hematological MalignanciesNot yet recruitingNCT07636486Phase 2/3
• Luspatercept in Preventing Poor Erythroid Engraftment for Hematological Malignancies With Moderate to Severe MyelofibrosisNot yet recruitingNCT07539779Phase 2/3
• The Efficacy and Safety of Luspatercept in Improving Early Anemia After HSCTNot yet recruitingNCT07450313Phase 2
• Luspatercept for the Treatment of Anemia Following Allogeneic Hematopoietic Stem Cell Transplantation(Allo-HSCT)RecruitingNCT07362095Phase 1/2
• Luspatercept in Patients Affected With Rare Inherited AnemiasNot yet recruitingNCT07331818Phase 2
• Luspatercept + Darbepoetin in MDSRecruitingNCT07096297Phase 2
• Treatment of Transfusion-dependent Nonsevere Aplastic Anemia With Luspatercept: a Multicenter Prospective Clinical StudyNot yet recruitingNCT06964971Not applicable
• AZA+Lus VS AZA Monotherapy in HR-MDSNot yet recruitingNCT06927232Phase 3
• Luspatercept for Clonal Cytopenias of Uncertain SignificanceRecruitingNCT06788691Phase 2
• Study of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent MyelofibrosisRecruitingNCT06517875Phase 2
• Clinical Observation of Luspatercept in Treatment of Chinese Adult β-thalassaemia Patients With TD β-thalassemiaRecruitingNCT06164821Not applicable
• The Tapering Dose of Luspatercept in Patients With Lower-risk Myelodysplastic SyndromesRecruitingNCT05925504Phase 2
• Efficacy and Safety of Luspatercept for the Treatment of Anemia Due to MDS With del5q, Refractory/Resistant/Intolerant to Prior Treatments, RBC-TDRecruitingNCT05924100Phase 2
• MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)RecruitingNCT05564390Phase 2
• Efficacy of Luspatercept in ESA-naive LR-MDS Patients With or Without Ring Sideroblasts Who do Not Require TransfusionsRecruitingNCT05384691Phase 2
• Study of Safety & PK of Luspatercept (ACE-536) in Pediatric Participants With Beta (β)-ThalassemiaRecruitingNCT04143724Phase 2
• A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical TrialsRecruitingNCT04064060Phase 3
• An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell TransfusionsActive, not recruitingNCT04717414Phase 3Results posted
• An Efficacy and Safety Study of Luspatercept (ACE-536) for the Treatment of Anemia Due to IPSS-R Very Low, Low or Intermediate Risk Myelodysplastic Syndromes (MDS) in Japanese Subjects Who Are Not Requiring Red Blood Cell TransfusionCompletedNCT03900715Phase 2Results posted
• A Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Participants Who Require Red Blood Cell Transfusions and Are ESA NaïveActive, not recruitingNCT03682536Phase 3Results posted
• A Study to Determine the Efficacy and Safety of Luspatercept in Adults With Non Transfusion Dependent Beta (β)-ThalassemiaCompletedNCT03342404Phase 2Results posted
• A Safety and Efficacy Study to Evaluate Luspatercept in Subjects With Myeloproliferative Neoplasm-associated Myelofibrosis Who Have Anemia With and Without Red Blood Cell-transfusion DependenceCompletedNCT03194542Phase 2Results posted
• A Study of Luspatercept (ACE-536) to Treat Anemia Due to Very Low, Low, or Intermediate Risk Myelodysplastic SyndromesCompletedNCT02631070Phase 3Results posted
• An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Adults Who Require Regular Red Blood Cell Transfusions Due to Beta (β) ThalassemiaCompletedNCT02604433Phase 3Results posted
• Extension Study to Evaluate the Safety and Efficacy of Luspatercept in Participants With β-Thalassemia Previously Enrolled in A536-04 (A536-06/MK-6143-004)CompletedNCT02268409Phase 2Results posted
• Extension Study to Evaluate Long-Term Effects of Luspatercept in Patients With Myelodysplastic Syndromes (MDS) (A536-05/MK-6143-003)CompletedNCT02268383Phase 2Results posted
• Study to Evaluate the Safety and Efficacy of Luspatercept (ACE-536) in Participants With Beta-thalassemia (A536-04/MK-6143-002)CompletedNCT01749540Phase 2Results posted
• Study of Luspatercept for the Treatment of Anemia in Patients With Myelodysplastic Syndrome (MDS) (MK-6143-001)CompletedNCT01749514Phase 2Results posted
• Luspatercept Plus CsA vs CsA for the Treatment of Newly Diagnosed Non-Transfusion-Dependent NSAAWithdrawnNCT06424639Phase 4
• Luspatercept in Metastatic AGCT of the OvaryCompletedNCT06254781Not applicable
• A Pilot, Open-Label Study of Luspatercept for Patients With Lower Risk Myelodysplastic Syndromes (MDS)Active, not recruitingNCT06113302Phase 2
• A Study to Assess Luspatercept in Lower-risk Myelodysplastic Syndrome ParticipantsActive, not recruitingNCT06045689Phase 3
• ELEMENT-MDS: A Study to Compare the Efficacy and Safety of Luspatercept in Participants With Myelodysplastic Syndrome (MDS) and Anemia Not Receiving Blood TransfusionsActive, not recruitingNCT05949684Phase 3
• A Study to Evaluate the Safety and Effectiveness of Luspatercept for the Treatment of Transfusion-dependent (TD) Anemia Associated With Myelodysplastic Syndromes (MDS) & Beta-thalassemia (β-Thal) in IndiaActive, not recruitingNCT05891249Phase 4
• Luspatercept for Anemia in Lower Risk MDS or Non-proliferative MDS/MPN NeoplasmsActive, not recruitingNCT05732961Phase 2
• A Study to Determine the Efficacy and Safety of Luspatercept in Adult Participants and to Evaluate the Safety and Pharmacokinetics in and Adolescent Participants With Alpha (α)-ThalassemiaActive, not recruitingNCT05664737Phase 2
• A Study to Evaluate Luspatercept (ACE-536) in Chinese Participants Who Require Regular Red Blood Cell Transfusions Due to Beta (β)-Thalassemia.Active, not recruitingNCT05567458Phase 2
• The Safety and Efficiency of Luspatercept in Chinese Adults With Transfusion Dependent β-thalassemia: a Real-world StudyStatus unknownNCT05462548Phase 4
• Efficacy and Safety in Transfusion Independent Non-severe Aplastic AnemiaCompletedNCT05399732Phase 2
• Assessment of Effectiveness and Safety of Luspatercept in Patients Suffering From Lower-risk Myelodysplastic Syndrome.Active, not recruitingNCT05181592Phase 3
• Luspatercept and Lenalidomide (L2) in Lower-risk, Non-del(5q) MDS PatientsSuspendedNCT04539236Phase 1/2
• A Study to Evaluate the Efficacy, Drug Levels and Safety of Luspatercept (ACE-536) for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes in Chinese and Japanese Participants With Ring Sideroblasts Who Require Red Blood Cell TransfusionsCompletedNCT04477850Phase 2
• Study of ACE-536 in Healthy Postmenopausal WomenCompletedNCT01432717Phase 1

← Luspatercept overview